TXE Procena debljine epikardnog adipoznog tkiva i sloja intima-media karotidne arterije kod bolesnika sa Behčetovom bolešću
Sažetak
Uvod/Cilj. Epidemiološke studije pokazuju da su kardiovaskularne bolesti (KVB) česte kod gotovo svih bolesnika sa dijagnozom autoimunske bolesti. Cilj ove studije bio je da ispita da li se debljina epikardnog masnog tkiva [epicardial adipose tissue (EAT) thickness (EATT)] i debljina sloja intima-media karotidne arterije [carotid intima-media (CIM) thickness (CIMT)], razlikuju između bolesnika sa Behčetovom bolešću (BB) i zdravih osoba. Metode. Ukupno 40 zdravih ispitanika u kontrolnoj grupi i 40 bolesnika sa BB sa tegobama mišićno-zglobnog sistema uključeno je u ovu prospektivnu studiju preseka. Dobijeni su socio-demografski, klinički i laboratorijski podaci koji su upoređeni između grupa. Za procenu aktivnosti bolesti korišćen je Behčetov obrazac trenutne aktivnosti bolesti. Obe grupe su podvrgnute ehokardiografiji radi merenja EATT i CIMT. Rezultati. Srednja vrednost EATT (5,70 ± 1,05 mm; 2,50 ± 0,61 mm, redom, p <0,001) i CIMT (0,68 ± 0,05 mm; 0,63 ± 0,06 mm, redom, p = 0,002) su bile značajno povećane kod bolesnika sa BB u poređenju sa kontrolnom grupom. Pozitivna korelacija je pokazana između EATT i starosti (r = 0,500, p = 0,001), vremena trajanja bolesti (r = 0,330, p < 0.001), obima struka (r = 0,316, p = 0,013) i aktivnosti bolesti (r = 0,31, p < 0,001) u grupi bolesnika. CIMT je pozitivno korelisao sa godinama života (r =0,594, p = 0,001) i vremenom trajanja bolesti (r = 0,585, p = 0,001). Upotreba glukokortikoida ili kliničke manifestacije (zahvaćenost zglobova, ulceracija na genitalijama, kožne lezije, upalni bol u leđima i zahvaćenost velikih organa) kod bolesnika nije bila povezana sa EATT ili CIMT. Zaključak. EATT i CIMT su povećane kod bolesnika sa BB i povezane su sa aktivnošću bolesti. Ehokardiografsko merenje EATT i CIMT je objektivna, neinvazivna i dostupna metoda koja može proceniti rizik od supkliničke ateroskleroze kod bolesnika sa BB.
Reference
1. Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin Rheumatol 2004; 16(1): 38‒42.
2. Silveira LH. Cardiovascular Manifestations of Systemic Vasculitides. Curr Rheumatol Rep 2020; 22(10): 72.
3. Farouk H, Zayed HS, El-Chilali K. Cardiac findings in patients with Behçet's disease: Facts and controversies. Anatol J Cardiol 2016; 16(7): 529‒33.
4. Geri G, Wechsler B, Thi Huong DL, Isnard R, Piette JC, Amoura Z, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore) 2012; 91(1): 25‒34.
5. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost 2012l; 38(5): 497‒505.
6. Cure E, Icli A, Ugur Uslu A, Aydoğan Baykara R, Sakiz D, Ozucan M, et al. Atherogenic index of plasma may be strong predictor of subclinical atherosclerosis in patients with Behçet disease. Z Rheumatol 2017; 76(3): 259‒66.
7. Merashli M, Ster IC, Ames PR. Subclinical atherosclerosis in Behcet's disease: A systematic review and meta-analysis. Semin Arthritis Rheum 2016; 45(4): 502‒10.
8. El-Shebiny E, El-Fakharany A, Zahran E, Shoeib S, Salem M, Elnaggar M, et al. Modifiable cardiovascular risk factors in patients with Behçet’s disease: a multicenter experience. Egypt J Int Med 2019; 31(4): 726‒32.
9. Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005; 52(10): 3045‒53.
10. Alexopoulos N, McLean DS, Janik M, Arepalli CD, Stillman AE, Raggi P. Epicardial adipose tissue and coronary artery plaque characteristics. Atherosclerosis 2010; 210(1): 150‒4.
11. Janik M, Hartlage G, Alexopoulos N, Mirzoyev Z, McLean DS, Arepalli CD, et al. Epicardial adipose tissue volume and coronary artery calcium to predict myocardial ischemia on positron emission tomography-computed tomography studies. J Nucl Cardiol 2010; 17(5): 841‒7.
12. Pierdomenico SD, Pierdomenico AM, Cuccurullo F, Iacobellis G. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2013; 111(1): 73‒8.
13. Nezu T, Hosomi N, Aoki S, Matsumoto M. Carotid Intima-Media Thickness for Atherosclerosis. J Atheroscler Thromb 2016; 23(1): 18‒31.
14. Ristić GG, Subota V, Lepić T, Stanisavljević D, Glišić B, Ristić AD, et al. Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis and Low Cardiovascular Risk: The Role of von Willebrand Factor Activity. PLoS One 2015; 10(8): e0130462.
15. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8(4): 437‒49.
16. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335(8697): 1078‒80.
17. Resorlu H, Akbal A, Resorlu M, Gokmen F, Ates C, Uysal F, et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol 2015; 34(2): 295‒9.
18. Petra CV, Albu A, Pamfil C, Tamas MM, Vesa SC, Rednic S. The relationship between epicardial adipose tissue and arterial stiffness in patients with rheumatoid arthritis. Med Ultrason 2019; 21(4): 427‒34.
19. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr 2009; 22(12): 1311‒9; quiz 1417‒8.
20. Tok D, Kadife I, Turak O, Ozcan F, Başar N, Cağlı K, et al. Increased epicardial fat thickness is associated with low grade systemic inflammation in metabolic syndrome. Turk Kardiyol Dern Ars 2012; 40(8): 690‒5.
21. Oflaz H, Mercanoglu F, Karaman O, Kamali S, Erer B, Genchellac H, et al. Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59(7): 777‒81.
22. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behçet's syndrome. J Am Coll Cardiol 2001; 37(2): 517‒20.
23. Chen H, Zhang Y, Li C, Wu W, Liu J, Zhang F, et al. Coronary involvement in patients with Behçet's disease. Clin Rheumatol 2019; 38(10): 2835‒41.
24. Sun BJ, Park JH, Yoo SJ, Park Y, Kim YJ, Lee IS, et al. Intrinsic changes of left ventricular function in patients with Behçet disease and comparison according to systemic disease activity. Echocardiography 2018; 35(6): 809‒16.
25. Escárcega RO, Lipinski MJ, García-Carrasco M, Mendoza-Pinto C, Galvez-Romero JL, Cervera R. Inflammation and atherosclerosis: Cardiovascular evaluation in patients with autoimmune diseases. Autoimmun Rev 2018; 17(7): 703‒8.
26. Szekanecz Z, Végh E, Váncsa A, Szamosi S, Szabó Z, Bodnár N, et al. Vascular rheumatology: atherosclerosis and cardiovascular disease in arthritis. Reumatologia/Rheumatology 2012, 50(4): 336‒44.
27. Hong SN, Park JC, Yoon NS, Lee SR, Kim KH, Hong YJ, et al. Carotid artery intima-media thickness in Behcet's disease patients without significant cardiovascular involvement. Korean J Intern Med 2008; 23(2): 87‒93.
28. Keser G, Aksu K, Tamsel S, Ozmen M, Kitapcioglu G, Kabaroglu C, et al. Increased thickness of the carotid artery intima-media assessed by ultrasonography in Behçet's disease. Clin Exp Rheumatol 2005; 23(4 Suppl 38): S71‒6.
29. Taşolar H, Taşolar S, Kurtuluş D, Altun B, Bayramoğlu A, Otlu YÖ, et al. Increased epicardial adipose tissue thickness on transthoracic echocardiography in patients with Behçet disease. J Ultrasound Med 2014; 33(8): 1393‒400.
30. Uslu Yurteri E, Üstüner E, Torgutalp M, Yayla ME, Okatan IE, Sezer S, et al. Can Subclinical Atherosclerosis Be Assessed More Precisely in Behçet Syndrome Patients by Using a Particular Cutoff Value for Carotid Intima-Media Thickness? J Clin Rheumatol 2021; doi: 10.1097/RHU.0000000000001643. (In Press)
31. Merashli M, Ster IC, Ames PR. Subclinical atherosclerosis in Behcet's disease: A systematic review and meta-analysis. Semin Arthritis Rheum 2016; 45(4): 502‒10.
32. Hassan S, Gheita T, Ghoneim S, Nasr L. Subclinical atherosclerosis in Behcet's disease. Arch Rheumatol 2012; 27(2): 109‒14.
33. Kotsis VT, Stabouli SV, Papamichael CM, Zakopoulos NA. Impact of obesity in intima-media thickness of carotid arteries. Obesity (Silver Spring) 2006; 14(10): 1708‒15.
34. Beauloye V, Zech F, Tran HT, Clapuyt P, Maes M, Brichard SM. Determinants of early atherosclerosis in obese children and adolescents. J Clin Endocrinol Metab 2007; 92(8): 3025‒32.
35. Bae JH, Kim WS, Rihal CS, Lerman A. Individual measurement and significance of carotid intima, media, and intima-media thickness by B-mode ultrasonographic image processing. Arterioscler Thromb Vasc Biol 2006; 26(10): 2380‒5.
36. Temiz A, Gökmen F, Gazi E, Akbal A, Barutçu A, Bekler A, et al. Epicardial adipose tissue thickness, flow-mediated dilatation of the brachial artery, and carotid intima-media thickness: Associations in rheumatoid arthritis patients. Herz 2015; 40(Suppl 3): 217‒24.
37. Tansey DK, Aly Z, Sheppard MN. Fat in the right ventricle of the normal heart. Histopathology 2005; 46(1): 98‒104.
38. Ormseth MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM, Bian A, et al. Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65(9): 1410–5.
39. Lima-Martínez MM, Campo E, Salazar J, Paoli M, Maldonado I, Acosta C, Rodney M, Contreras M, Cabrera-Rego JO, Iacobellis G. Epicardial fat thickness as cardiovascular risk factor and therapeutic target in patients with rheumatoid arthritis treated with biological and nonbiological therapies. Arthritis 2014; 2014: 782850.
40. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015; 67(6): 1449‒55.
41. Nurmohamed MT. Editorial: treat to target in rheumatoid arthritis: good for the joints as well as the heart? Arthritis Rheumatol 2015; 67(6): 1412‒5.
42. MacLeod C, Hadoke PWF, Nixon M. Glucocorticoids: Fuelling the Fire of Atherosclerosis or Therapeutic Extinguishers? Int J Mol Sci. 2021;22(14):7622.
43. Fava C, Montagnana M. Atherosclerosis Is an Inflammatory Disease Which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review. Front Pharmacol 2018; 9: 55.